Related references
Note: Only part of the references are listed.Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
Susanne Saussele et al.
ACTA HAEMATOLOGICA (2020)
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini et al.
BLOOD (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
Weiqi Huang et al.
LEUKEMIA (2020)
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries
Anna Turkina et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
Yazad D. Irani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
Shinya Kimura et al.
LANCET HAEMATOLOGY (2020)
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
Massimo Breccia et al.
CANCER MEDICINE (2020)
Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores
Javeria Aijaz et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Onyee Chan et al.
BLOOD ADVANCES (2020)
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
Carmen Fava et al.
HAEMATOLOGICA (2019)
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
Birgit Spiess et al.
PLOS ONE (2019)
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay
Lasse Kjaer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US
Elias J. Jabbour et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
Aytug Kizilors et al.
LANCET HAEMATOLOGY (2019)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
Kang-kang Chen et al.
FRONTIERS IN ONCOLOGY (2019)
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini et al.
CLINICAL CANCER RESEARCH (2019)
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key?
Simona Bernardi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2019)
New approaches to molecular monitoring in CML (and other diseases)
Jerald Radich et al.
BLOOD (2019)
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
Michele Baccarani et al.
LEUKEMIA (2019)
Advantages of digital PCR in the detection of low abundance BCR-ABL1 gene in patients with chronic myeloid leukemia
Zhiling Yan et al.
ONCOLOGY LETTERS (2019)
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
Ya-Chen Tina Shih et al.
LANCET HAEMATOLOGY (2019)
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
Barbara Izzo et al.
FRONTIERS IN ONCOLOGY (2019)
Bone marrow microenvironment: The guardian of leukemia stem cells
Mohammad Houshmand et al.
WORLD JOURNAL OF STEM CELLS (2019)
Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
Zhanglin Zhang et al.
BMC CANCER (2019)
Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia
Simona Bernardi et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2019)
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
Fabien Muselli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Luana Bavaro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution
Masaki Iino et al.
HEMATOLOGY (2019)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group
Delphine Rea et al.
CANCER (2018)
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia et al.
FRONTIERS IN ONCOLOGY (2018)
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia
Sabrina Inselmann et al.
CANCER RESEARCH (2018)
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Juan Carlos Hernandez-Boluda et al.
BLOOD CANCER JOURNAL (2018)
Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
Sunita Chhikara et al.
SOUTH ASIAN JOURNAL OF CANCER (2018)
We do still transplant CML, don't we?
Charles F. Craddock
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much
Robert Peter Gale et al.
LEUKEMIA RESEARCH (2017)
Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Danilo Perrotti et al.
CURRENT DRUG TARGETS (2017)
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Priyanka A. Pophali et al.
CANCER JOURNAL (2016)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
Constance Baer et al.
HAEMATOLOGICA (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
Constance Baer et al.
HAEMATOLOGICA (2016)
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death
Markus Pfirrmann et al.
ANNALS OF HEMATOLOGY (2015)
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani et al.
ANNALS OF HEMATOLOGY (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
D. Russo et al.
BLOOD CANCER JOURNAL (2015)
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
Katerina Machova Polakova et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase
Bei Hu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia
Elias J. Jabbour et al.
LEUKEMIA & LYMPHOMA (2014)
Imatinib in Chronic Myeloid Leukemia: an Overview
Tomasz Sacha
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
Tyrosine Kinase Inhibitors and Interferon
Maria Dimou et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini et al.
BLOOD (2013)
Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Domenico Russo et al.
CURRENT CANCER DRUG TARGETS (2013)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Share Paper
